Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Alnylam Pharmaceuticals and maintained a price target of $320.
October 10, 2024 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Alnylam Pharmaceuticals and maintained a price target of $320, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $320 price target by Needham suggests positive sentiment and confidence in Alnylam's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100